nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—L-Phenylalanine—Melphalan—peripheral nervous system neoplasm	0.612	1	CrCrCtD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—PINK1—peripheral nervous system neoplasm	0.00391	0.087	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.00334	0.0744	CbGpPWpGaD
Dextroamphetamine—L-Phenylalanine—TH—peripheral nervous system neoplasm	0.00309	0.584	CrCbGaD
Dextroamphetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.00289	0.0644	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00211	0.0469	CbGpPWpGaD
Dextroamphetamine—Ephedrine—BCHE—peripheral nervous system neoplasm	0.0017	0.322	CrCbGaD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.00164	0.0366	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	0.00158	0.0353	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.0013	0.0289	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00103	0.023	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00102	0.0227	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00101	0.0225	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	0.000944	0.021	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Alpha-synuclein signaling—TH—peripheral nervous system neoplasm	0.000919	0.0205	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—TH—peripheral nervous system neoplasm	0.000896	0.02	CbGpPWpGaD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.000853	0.019	CbGpPWpGaD
Dextroamphetamine—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000808	0.0024	CcSEcCtD
Dextroamphetamine—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.000801	0.00237	CcSEcCtD
Dextroamphetamine—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000798	0.00237	CcSEcCtD
Dextroamphetamine—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000797	0.00236	CcSEcCtD
Dextroamphetamine—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000793	0.00235	CcSEcCtD
Dextroamphetamine—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000793	0.00235	CcSEcCtD
Dextroamphetamine—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000791	0.00234	CcSEcCtD
Dextroamphetamine—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000791	0.00234	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000788	0.0175	CbGpPWpGaD
Dextroamphetamine—Chest pain—Alitretinoin—peripheral nervous system neoplasm	0.000787	0.00233	CcSEcCtD
Dextroamphetamine—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000787	0.00233	CcSEcCtD
Dextroamphetamine—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000787	0.00233	CcSEcCtD
Dextroamphetamine—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000787	0.00233	CcSEcCtD
Dextroamphetamine—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000787	0.00233	CcSEcCtD
Dextroamphetamine—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.000784	0.00233	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000784	0.00232	CcSEcCtD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—TH—peripheral nervous system neoplasm	0.000781	0.0174	CbGpPWpGaD
Dextroamphetamine—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000781	0.00231	CcSEcCtD
Dextroamphetamine—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.000776	0.0023	CcSEcCtD
Dextroamphetamine—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000772	0.00229	CcSEcCtD
Dextroamphetamine—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.00077	0.00228	CcSEcCtD
Dextroamphetamine—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000769	0.00228	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000755	0.0168	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000754	0.00224	CcSEcCtD
Dextroamphetamine—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00075	0.00222	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000739	0.00219	CcSEcCtD
Dextroamphetamine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000738	0.00219	CcSEcCtD
Dextroamphetamine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000736	0.00218	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000733	0.00217	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000733	0.00217	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.000729	0.00216	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000727	0.00216	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000724	0.00215	CcSEcCtD
Dextroamphetamine—Infection—Vincristine—peripheral nervous system neoplasm	0.000722	0.00214	CcSEcCtD
Dextroamphetamine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00072	0.00213	CcSEcCtD
Dextroamphetamine—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000719	0.00213	CcSEcCtD
Dextroamphetamine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000714	0.00212	CcSEcCtD
Dextroamphetamine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000714	0.00212	CcSEcCtD
Dextroamphetamine—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000707	0.0021	CcSEcCtD
Dextroamphetamine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000705	0.00209	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.000703	0.00208	CcSEcCtD
Dextroamphetamine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000702	0.00208	CcSEcCtD
Dextroamphetamine—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000693	0.00205	CcSEcCtD
Dextroamphetamine—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000687	0.00204	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.000685	0.00203	CcSEcCtD
Dextroamphetamine—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000682	0.00202	CcSEcCtD
Dextroamphetamine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000682	0.00202	CcSEcCtD
Dextroamphetamine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000681	0.00202	CcSEcCtD
Dextroamphetamine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000681	0.00202	CcSEcCtD
Dextroamphetamine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000673	0.00199	CcSEcCtD
Dextroamphetamine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000672	0.00199	CcSEcCtD
Dextroamphetamine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000671	0.00199	CcSEcCtD
Dextroamphetamine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000668	0.00198	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000665	0.00197	CcSEcCtD
Dextroamphetamine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000664	0.00197	CcSEcCtD
Dextroamphetamine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000664	0.00197	CcSEcCtD
Dextroamphetamine—Affect lability—Epirubicin—peripheral nervous system neoplasm	0.000661	0.00196	CcSEcCtD
Dextroamphetamine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000658	0.00195	CcSEcCtD
Dextroamphetamine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000658	0.00195	CcSEcCtD
Dextroamphetamine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000658	0.00195	CcSEcCtD
Dextroamphetamine—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000656	0.00194	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000651	0.00193	CcSEcCtD
Dextroamphetamine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00065	0.00193	CcSEcCtD
Dextroamphetamine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000645	0.00191	CcSEcCtD
Dextroamphetamine—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000643	0.00191	CcSEcCtD
Dextroamphetamine—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000643	0.00191	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000643	0.00191	CcSEcCtD
Dextroamphetamine—Infection—Cisplatin—peripheral nervous system neoplasm	0.000639	0.00189	CcSEcCtD
Dextroamphetamine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000638	0.00189	CcSEcCtD
Dextroamphetamine—Mood swings—Epirubicin—peripheral nervous system neoplasm	0.000636	0.00189	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000634	0.00188	CcSEcCtD
Dextroamphetamine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000633	0.00188	CcSEcCtD
Dextroamphetamine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000633	0.00188	CcSEcCtD
Dextroamphetamine—Rash—Topotecan—peripheral nervous system neoplasm	0.000633	0.00188	CcSEcCtD
Dextroamphetamine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000632	0.00187	CcSEcCtD
Dextroamphetamine—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000632	0.00187	CcSEcCtD
Dextroamphetamine—Headache—Topotecan—peripheral nervous system neoplasm	0.000629	0.00186	CcSEcCtD
Dextroamphetamine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000628	0.00186	CcSEcCtD
Dextroamphetamine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000628	0.00186	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000628	0.00186	CcSEcCtD
Dextroamphetamine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000627	0.00186	CcSEcCtD
Dextroamphetamine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000627	0.00186	CcSEcCtD
Dextroamphetamine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000627	0.00186	CcSEcCtD
Dextroamphetamine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000627	0.00186	CcSEcCtD
Dextroamphetamine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000625	0.00185	CcSEcCtD
Dextroamphetamine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000625	0.00185	CcSEcCtD
Dextroamphetamine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000624	0.00185	CcSEcCtD
Dextroamphetamine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000624	0.00185	CcSEcCtD
Dextroamphetamine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000623	0.00185	CcSEcCtD
Dextroamphetamine—Constipation—Vincristine—peripheral nervous system neoplasm	0.000622	0.00184	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000621	0.00184	CcSEcCtD
Dextroamphetamine—Rash—Melphalan—peripheral nervous system neoplasm	0.00062	0.00184	CcSEcCtD
Dextroamphetamine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000619	0.00184	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000617	0.00183	CcSEcCtD
Dextroamphetamine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000614	0.00182	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000613	0.00182	CcSEcCtD
Dextroamphetamine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000613	0.00182	CcSEcCtD
Dextroamphetamine—Affect lability—Doxorubicin—peripheral nervous system neoplasm	0.000612	0.00181	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000605	0.00179	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.0006	0.00178	CcSEcCtD
Dextroamphetamine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000599	0.00178	CcSEcCtD
Dextroamphetamine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000596	0.00177	CcSEcCtD
Dextroamphetamine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000596	0.00177	CcSEcCtD
Dextroamphetamine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000596	0.00177	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000595	0.00176	CcSEcCtD
Dextroamphetamine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000591	0.00175	CcSEcCtD
Dextroamphetamine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000591	0.00175	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000589	0.00175	CcSEcCtD
Dextroamphetamine—Mood swings—Doxorubicin—peripheral nervous system neoplasm	0.000589	0.00175	CcSEcCtD
Dextroamphetamine—Infection—Etoposide—peripheral nervous system neoplasm	0.000585	0.00173	CcSEcCtD
Dextroamphetamine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000584	0.00173	CcSEcCtD
Dextroamphetamine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000584	0.00173	CcSEcCtD
Dextroamphetamine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000575	0.0017	CcSEcCtD
Dextroamphetamine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000575	0.0017	CcSEcCtD
Dextroamphetamine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000575	0.0017	CcSEcCtD
Dextroamphetamine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000573	0.0017	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000569	0.00169	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000568	0.00168	CcSEcCtD
Dextroamphetamine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000561	0.00166	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.00056	0.00166	CcSEcCtD
Dextroamphetamine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000559	0.00166	CcSEcCtD
Dextroamphetamine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000557	0.00165	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000556	0.00165	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000555	0.00165	CcSEcCtD
Dextroamphetamine—ADRA1A—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.000552	0.0123	CbGpPWpGaD
Dextroamphetamine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000541	0.0016	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000536	0.00159	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.00053	0.00157	CcSEcCtD
Dextroamphetamine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000525	0.00156	CcSEcCtD
Dextroamphetamine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000525	0.00156	CcSEcCtD
Dextroamphetamine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000524	0.00155	CcSEcCtD
Dextroamphetamine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000522	0.00155	CcSEcCtD
Dextroamphetamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000517	0.00153	CcSEcCtD
Dextroamphetamine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000516	0.00153	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000513	0.00152	CcSEcCtD
Dextroamphetamine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000513	0.00152	CcSEcCtD
Dextroamphetamine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000512	0.00152	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000508	0.00151	CcSEcCtD
Dextroamphetamine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000508	0.00151	CcSEcCtD
Dextroamphetamine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000508	0.00151	CcSEcCtD
Dextroamphetamine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000504	0.00149	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000503	0.00149	CcSEcCtD
Dextroamphetamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000499	0.00148	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000497	0.00147	CcSEcCtD
Dextroamphetamine—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000496	0.00147	CcSEcCtD
Dextroamphetamine—Selegiline—ABCB1—peripheral nervous system neoplasm	0.000494	0.0934	CrCbGaD
Dextroamphetamine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.00049	0.00145	CcSEcCtD
Dextroamphetamine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000486	0.00144	CcSEcCtD
Dextroamphetamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000483	0.00143	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000482	0.00143	CcSEcCtD
Dextroamphetamine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000481	0.00143	CcSEcCtD
Dextroamphetamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00048	0.00142	CcSEcCtD
Dextroamphetamine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000476	0.00141	CcSEcCtD
Dextroamphetamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000475	0.00141	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000475	0.00141	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000474	0.0014	CcSEcCtD
Dextroamphetamine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000473	0.0014	CcSEcCtD
Dextroamphetamine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000468	0.00139	CcSEcCtD
Dextroamphetamine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000466	0.00138	CcSEcCtD
Dextroamphetamine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000466	0.00138	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000466	0.00138	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000465	0.0103	CbGpPWpGaD
Dextroamphetamine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000462	0.00137	CcSEcCtD
Dextroamphetamine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000461	0.00137	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000459	0.00136	CcSEcCtD
Dextroamphetamine—Rash—Vincristine—peripheral nervous system neoplasm	0.000458	0.00136	CcSEcCtD
Dextroamphetamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000458	0.00136	CcSEcCtD
Dextroamphetamine—Headache—Vincristine—peripheral nervous system neoplasm	0.000455	0.00135	CcSEcCtD
Dextroamphetamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000448	0.00133	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000445	0.00991	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00044	0.0013	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000439	0.0013	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000434	0.00129	CcSEcCtD
Dextroamphetamine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000432	0.00128	CcSEcCtD
Dextroamphetamine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000423	0.00125	CcSEcCtD
Dextroamphetamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000409	0.00121	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000407	0.00121	CcSEcCtD
Dextroamphetamine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000405	0.0012	CcSEcCtD
Dextroamphetamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000405	0.0012	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000404	0.009	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000403	0.00119	CcSEcCtD
Dextroamphetamine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000397	0.00118	CcSEcCtD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000395	0.0088	CbGpPWpGaD
Dextroamphetamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000393	0.00116	CcSEcCtD
Dextroamphetamine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000389	0.00115	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000388	0.00863	CbGpPWpGaD
Dextroamphetamine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000382	0.00113	CcSEcCtD
Dextroamphetamine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000374	0.00111	CcSEcCtD
Dextroamphetamine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000372	0.0011	CcSEcCtD
Dextroamphetamine—Rash—Etoposide—peripheral nervous system neoplasm	0.000371	0.0011	CcSEcCtD
Dextroamphetamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000371	0.0011	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000369	0.00822	CbGpPWpGaD
Dextroamphetamine—Headache—Etoposide—peripheral nervous system neoplasm	0.000369	0.00109	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000367	0.00109	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000364	0.00108	CcSEcCtD
Dextroamphetamine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000357	0.00106	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000354	0.00788	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000353	0.00787	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000351	0.00781	CbGpPWpGaD
Dextroamphetamine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.00035	0.00104	CcSEcCtD
Dextroamphetamine—Nausea—Etoposide—peripheral nervous system neoplasm	0.00035	0.00104	CcSEcCtD
Dextroamphetamine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000349	0.00104	CcSEcCtD
Dextroamphetamine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000344	0.00102	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000344	0.00102	CcSEcCtD
Dextroamphetamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000343	0.00102	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000337	0.00751	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000337	0.000999	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000331	0.000981	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.00033	0.000979	CcSEcCtD
Dextroamphetamine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000328	0.000972	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000324	0.000961	CcSEcCtD
Dextroamphetamine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000323	0.000958	CcSEcCtD
Dextroamphetamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000955	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000319	0.000946	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.000945	CcSEcCtD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—peripheral nervous system neoplasm	0.000318	0.00708	CbGpPWpGaD
Dextroamphetamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000941	CcSEcCtD
Dextroamphetamine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000315	0.000933	CcSEcCtD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000314	0.00699	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000312	0.000924	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00031	0.00689	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000306	0.00682	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000906	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000305	0.00679	CbGpPWpGaD
Dextroamphetamine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.0009	CcSEcCtD
Dextroamphetamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000299	0.000885	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000884	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.000875	CcSEcCtD
Dextroamphetamine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000294	0.000873	CcSEcCtD
Dextroamphetamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000293	0.00087	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.000863	CcSEcCtD
Dextroamphetamine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000862	CcSEcCtD
Dextroamphetamine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000287	0.000851	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000286	0.00636	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000285	0.000845	CcSEcCtD
Dextroamphetamine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000285	0.000844	CcSEcCtD
Dextroamphetamine—SLC18A2—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000283	0.0063	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000283	0.0063	CbGpPWpGaD
Dextroamphetamine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000282	0.000837	CcSEcCtD
Dextroamphetamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000819	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000274	0.0061	CbGpPWpGaD
Dextroamphetamine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000807	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000805	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.00027	0.00601	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.00027	0.0008	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000797	CcSEcCtD
Dextroamphetamine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.000787	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.000782	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000781	CcSEcCtD
Dextroamphetamine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000778	CcSEcCtD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000262	0.00583	CbGpPWpGaD
Dextroamphetamine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000774	CcSEcCtD
Dextroamphetamine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000774	CcSEcCtD
Dextroamphetamine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000774	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000741	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000243	0.000721	CcSEcCtD
Dextroamphetamine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000719	CcSEcCtD
Dextroamphetamine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000716	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000716	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000239	0.00532	CbGpPWpGaD
Dextroamphetamine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000237	0.000702	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000234	0.0052	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000232	0.00518	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000229	0.0051	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000226	0.00067	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000667	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.00022	0.0049	CbGpPWpGaD
Dextroamphetamine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.00065	CcSEcCtD
Dextroamphetamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000218	0.000647	CcSEcCtD
Dextroamphetamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000622	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.00062	CcSEcCtD
Dextroamphetamine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000617	CcSEcCtD
Dextroamphetamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000617	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000207	0.00461	CbGpPWpGaD
Dextroamphetamine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000613	CcSEcCtD
Dextroamphetamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000599	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.0002	0.00445	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000199	0.00444	CbGpPWpGaD
Dextroamphetamine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000581	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000576	CcSEcCtD
Dextroamphetamine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000571	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.00057	CcSEcCtD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000192	0.00428	CbGpPWpGaD
Dextroamphetamine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000567	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000191	0.00425	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	0.000186	0.00415	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000184	0.00411	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—CASP3—peripheral nervous system neoplasm	0.000182	0.00406	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000182	0.00404	CbGpPWpGaD
Dextroamphetamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000538	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000181	0.00403	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000178	0.00395	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000177	0.00394	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000175	0.00389	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.00017	0.00379	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00017	0.00378	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000169	0.00375	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000167	0.00372	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	0.000165	0.00368	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000163	0.00364	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000159	0.00354	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000159	0.00354	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000158	0.00351	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000145	0.00323	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000141	0.00314	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000125	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000118	0.00262	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000117	0.0026	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000115	0.00255	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000113	0.00251	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—HRAS—peripheral nervous system neoplasm	0.000112	0.00249	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.00011	0.00246	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—peripheral nervous system neoplasm	0.00011	0.00245	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000107	0.00239	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000104	0.00233	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000102	0.00228	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000102	0.00228	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.0001	0.00223	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—AKT1—peripheral nervous system neoplasm	9.88e-05	0.0022	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	9.8e-05	0.00218	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—peripheral nervous system neoplasm	9.79e-05	0.00218	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	9.76e-05	0.00217	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	9.65e-05	0.00215	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.38e-05	0.00209	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—AKT1—peripheral nervous system neoplasm	9.3e-05	0.00207	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	9.08e-05	0.00202	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	8.95e-05	0.00199	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	8.71e-05	0.00194	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	8.66e-05	0.00193	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	8.65e-05	0.00193	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	8.57e-05	0.00191	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	8.53e-05	0.0019	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—AKT1—peripheral nervous system neoplasm	8.26e-05	0.00184	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.96e-05	0.00177	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	7.95e-05	0.00177	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	7.85e-05	0.00175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	7.83e-05	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	7.75e-05	0.00173	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	7.71e-05	0.00172	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	7.58e-05	0.00169	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	7.15e-05	0.00159	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.96e-05	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	6.95e-05	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	6.88e-05	0.00153	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.83e-05	0.00152	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.64e-05	0.00148	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—HRAS—peripheral nervous system neoplasm	6.64e-05	0.00148	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.52e-05	0.00145	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	6.35e-05	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.04e-05	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	5.8e-05	0.00129	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.79e-05	0.00129	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.37e-05	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	5.37e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	5.16e-05	0.00115	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.15e-05	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	5.15e-05	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.14e-05	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.06e-05	0.00113	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.86e-05	0.00108	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.72e-05	0.00105	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.68e-05	0.00104	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	4.6e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.58e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	4.49e-05	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	4.42e-05	0.000985	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.29e-05	0.000955	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	4.24e-05	0.000945	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.23e-05	0.000941	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	4.08e-05	0.000909	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.07e-05	0.000905	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.02e-05	0.000895	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	3.96e-05	0.000881	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.93e-05	0.000875	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.92e-05	0.000873	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	3.89e-05	0.000865	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	3.77e-05	0.000839	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.75e-05	0.000836	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	3.73e-05	0.000829	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.65e-05	0.000813	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	3.59e-05	0.000798	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.57e-05	0.000795	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.17e-05	0.000707	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3e-05	0.000668	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.87e-05	0.000639	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.82e-05	0.000628	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.79e-05	0.000622	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.71e-05	0.000604	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.59e-05	0.000576	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.53e-05	0.000564	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.48e-05	0.000552	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.41e-05	0.000537	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.37e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	2.35e-05	0.000524	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.3e-05	0.000512	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.11e-05	0.000469	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	1.99e-05	0.000443	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.9e-05	0.000422	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	1.87e-05	0.000416	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.68e-05	0.000374	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.65e-05	0.000367	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	1.53e-05	0.00034	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.5e-05	0.000334	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.49e-05	0.000332	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.47e-05	0.000326	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.3e-05	0.00029	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.23e-05	0.000273	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.19e-05	0.000266	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.18e-05	0.000263	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.16e-05	0.000258	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.09e-05	0.000243	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.08e-05	0.000241	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.06e-05	0.000236	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.05e-05	0.000234	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.92e-06	0.000221	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	9.63e-06	0.000215	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.24e-06	0.000206	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.81e-06	0.000196	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.21e-06	0.000183	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.59e-06	0.000169	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.26e-06	0.000162	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.74e-06	0.00015	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.45e-06	0.000144	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.41e-06	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.69e-06	0.000127	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	4.12e-06	9.17e-05	CbGpPWpGaD
